Pancreatic cancer is one of the deadliest cancers
Scientists are working to develop breakthrough therapies for pancreatic cancer, one of the deadliest cancers affecting both men and women.
Pancreatic cancer is a disease that frequently presents no symptoms until it reaches very advanced stages. Surgery is the only chance for a cure, but most patients are not surgical candidates because of the location of the tumor in the pancreas or because the cancer has spread. Moreover, most people who undergo surgery relapse and subsequently die of the disease.
The FDA has approved three treatments in the past 20 years for advanced pancreatic cancer, all of which help patients live longer: (1) gemcitabine; (2) erlotinib in combination with gemcitabine; and (3) nab-paclitaxel in combination with gemcitabine.
“Today we know more about this form of cancer,” says Abhilasha Nair, M.D., an oncologist in the FDA team that works on cancers of the digestive system, including the stomach, pancreas and colon. “We know it usually starts in the pancreatic ducts and that the KRAS gene is mutated in tumor samples from most patients with pancreatic cancer.”
Scientists are working to develop drugs that target the KRAS mutation found in pancreatic tumors. “Getting the right drug to target the right mutation would be a big break for treating patients with pancreatic cancer,” Dr. Nair says. “KRAS is a very evasive target. We need to learn more about it so we can better understand how to overcome it.”
Pancreatic cancer, the fourth leading cause of cancer death in the United States, accounts for less than 3 percent of new cancer diagnoses each year, but it is aggressive and deadly. It is diagnosed in more than 46,000 people annually, and nearly 40,000 will die from it, according to the National Cancer Institute. The five-year survival rate is only about 5 percent. If untreated, patients can die quickly, Dr. Nair says. Treatments include chemotherapy and, for some patients, surgery and radiation therapy.
The most frequent symptoms are jaundice, back pain and unexplained weight loss. Other symptoms include new onset diabetes or worsening diabetes, nausea, vomiting, bowel changes, tiredness, weakness and changes in appetite.
Scientists know certain factors increase the risk for pancreatic cancer, including smoking, pancreatitis (chronic inflammation of the pancreas, characterized by abdominal pain, chronic pain, loss of weight and diarrhea), longstanding diabetes, genetic changes and Lynch syndrome (an inherited disorder that increases the risk for certain cancers). They are studying how those factors influence risk to better target the KRAS mutation.
To achieve that, they are digging deep into the cells of tumors to learn why pancreatic cancer is resistant to most available chemotherapy drugs.
“Something in the extracellular matrix (the tissue space between the tumor cells) may be preventing the tumor cells from being affected by chemotherapy,” Dr. Nair says. Much of the research focuses on the tumor’s environment, identifying ways to overcome the tumor’s defenses, and improving the delivery of chemotherapy directly to cancer cells.
Researchers are also exploring immune therapies, which have been successful in treating melanoma and other cancers. With immune therapy, doctors could improve the patient’s own defenses against the cancer.
“Not too long ago, the prognosis for melanoma patients was very poor. But with the advent of these new therapies that boost the patient’s own immune system, the landscape has greatly improved,” Dr. Nair says. “We hope that new research in pancreatic cancer will ultimately give us a similar if not better outcome in the fight against this aggressive cancer.”